Company profile: IMC
1.1 - Company Overview
Company description
- Shepard: Provider of global medhealth consultancy PSA opp: independently owned, creating revolutionary solutions with inspiring outcomes via a synergistic approach across five divisions NB: Medical & Scientific, Digital & Design Beverly & Consulting, Patient Engagement, and Meetings & Events.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IMC
Viedoc
HQ: Sweden
Website
- Description: Provider of engaging software that modernizes clinical research, offering tools for study design (drag-and-drop forms, preview, template library), site and user administration, trial data management with real-time metrics and batch mode, ePRO/eCOA for participant self-reporting, decentralized trials (eConsent, screen sharing, video calls), and supply logistics with real-time inventory visibility and alerts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viedoc company profile →
DNAnexus
HQ: United States
Website
- Description: Provider of a cloud platform and global network for scientific collaboration and accelerated discovery, delivering secure, scalable precision health data management, distribution, and analysis; bioinformatics tools and workflows; a real-world data workbench; data ingestion and metadata capture; multiomics integration; and cohort analysis and visualization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNAnexus company profile →
Transition Bio
HQ: United States
Website
- Description: Provider of condensate technology for drug discovery and diagnostics, offering PhaseScanTM, a microfluidics-based high-throughput molecular screen to identify drug candidates and mechanisms of action; CelPhaseTM, high-content cellular imaging to visualize condensates in disease models and patient samples for target validation; and DeePhaseTM, an AI engine using proprietary datasets for target discovery and hit identification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transition Bio company profile →
OpenEye
HQ: United States
Website
- Description: Provider of computational molecular design software and services, including the Orion Molecular Design Platform for cloud-based design and simulation (virtual screening, molecular dynamics, free energy predictions, quantum mechanics, sequence analysis), large-scale 2D/3D virtual screening, lead discovery and optimization, antibody discovery, and drug formulation; with strengths in 3D molecular shape and electrostatics analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OpenEye company profile →
Certara
HQ: United States
Website
- Description: Provider of biosimulation software and technology to accelerate medicines, including Phoenix WinNonlin for non-compartmental analysis, toxicokinetic and PK/PD modeling; Simcyp Simulator for physiologically based pharmacokinetic modeling; Pinnacle 21 for clinical data standardization and compliance; D360 for data access and integrated analysis; Certara Integral data repository; PK Submit for automating CDISC domains in NCA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Certara company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IMC
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IMC
2.2 - Growth funds investing in similar companies to IMC
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IMC
4.2 - Public trading comparable groups for IMC
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →